Date of Last Revision

2023-05-02 20:39:52

Degree Name

Bachelor of Science

Date of Expected Graduation

Summer 2016


Inflammation is a significant component of neurological diseases such as multiple sclerosis (MS). One potential anti-inflammatory agent, rolipram, was tested for efficacy in MS; however, despite showing promise in early trials, the drug has been largely sidelined due to side effects. However, it is still of interest to elucidate the anti-inflammatory mechanisms of rolipram in order to identify more targeted inhibitors of inflammatory signaling. In order to achieve this end, we have utilized liquid chromatography-mass spectrometry-based metabolomics to determine metabolic pathways that are altered by rolipram treatment in human THP-1 monocytic cells and primary mouse microglial cultures. Amino acids and related metabolites as well as steroid species were identified as being significantly dysregulated. Shotgun lipidomics showed upregulation of glycerophospholipids, including phosphatidylcholine and phosphatidylserine after rolipram treatment. Taken together, these results suggest that rolipram inhibition of cAMP breakdown leads to significant alterations on the metabolome of monocytic immune cells.

Research Sponsor

Dr. Leah Shriver

First Reader

Dr. Jordan Renna

Second Reader

Dr. Rolando J.J. Ramirez

Included in

Biology Commons



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.